Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Trametinib + Triciribine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Trametinib||Mekinist||GSK1120212||MEK inhibitor (Pan) 23 MEK1 Inhibitor 25 MEK2 Inhibitor 23||Mekinist (trametinib) inhibits MEK 1 and 2, which potentially leads to reduced tumor cell proliferation (PMID: 27956260). Mekinist (trametinib) is FDA approved for melanoma patients harboring BRAF V600E or BRAF V600K mutations, and in combination with Tafinlar (dabrafenib) for BRAF V600E/K-mutant melanoma, BRAF V600E- mutant non-small cell lung cancer, BRAF V600E-mutant anaplastic thyroid cancer, for adult and pediatric patients of 6 years or older with unresectable or metastatic solid tumors harboring BRAF V600E, and for pediatric patients of 1 year or older with low-grade glioma harboring BRAF V600E (FDA.gov).|
|Triciribine||VQD-002|API-2||Akt Inhibitor (Pan) 21||Triciribine (API-2) is a purine analog that inhibits DNA synthesis, and blocks Akt phosphorylation, which may reduce proliferation and promote apoptosis in cancer cells (PMID: 21636709, PMID: 19422047).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|